


# PRODUCT INFORMATION



## NVP-TAE226

Item No. 17685

CAS Registry No.: 761437-28-9  
Formal Name: 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-benzamide  
Synonym: TAE226  
MF:  $C_{23}H_{25}ClN_6O_3$   
FW: 468.9  
Purity:  $\geq 98\%$   
UV/Vis.:  $\lambda_{max}$ : 285 nm  
Supplied as: A crystalline solid  
Storage:  $-20^{\circ}\text{C}$   
Stability:  $\geq 4$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

NVP-TAE226 is supplied as a crystalline solid. A stock solution may be made by dissolving the NVP-TAE226 in the solvent of choice, which should be purged with an inert gas. NVP-TAE226 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of NVP-TAE226 in these solvents is approximately 10 and 30 mg/ml, respectively.

NVP-TAE226 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NVP-TAE226 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. NVP-TAE226 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

NVP-TAE226 is an inhibitor of focal adhesion kinase (FAK;  $IC_{50} = 5.5$  nM) and the related protein-rich tyrosine kinase 2- $\beta$  (PYK2 $\beta$ ;  $IC_{50} = 5$  nM).<sup>1</sup> It can also inhibit the insulin-like growth factor 1 receptor ( $IC_{50} = 0.16$   $\mu\text{M}$ ) as well as the activity of its downstream target genes such as MAPK and Akt.<sup>1</sup> NVP-TAE226 has been shown to inhibit glioma and ovarian tumor growth in *in vivo* tumor models.<sup>2</sup>

### References

1. Liu, T.-J., LaFortune, T., Honda, T., *et al.* Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation *in vitro* and *in vivo*. *Mol. Cancer Ther.* **6**(4), 1357-1367 (2007).
2. Halder, J., Lin, Y.G., Merritt, W.M., *et al.* Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. *Cancer Research* **67**(22), 10976-10983 (2007).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM